Fig. 2: Survival profiles by CAR-T therapy in R/R B-ALL patients. | Cell Death & Disease

Fig. 2: Survival profiles by CAR-T therapy in R/R B-ALL patients.

From: Treatment response, survival, safety, and predictive factors to chimeric antigen receptor T cell therapy in Chinese relapsed or refractory B cell acute lymphoblast leukemia patients

Fig. 2

The median EFS was 11.6 months, and the possibility of EFS was 58.5% at M6 and 44.8% at M12 (a). The median OS was 14.0 months, and the possibility of OS was 81.1% at M6 and 54.8 at M12 (b). Kaplan–Meier curve was used to demonstrate survival profiles. EFS, event-free survival; OS, overall survival; M6, 6 months; M12, 12 months.

Back to article page